Related Experiment Video
Updated: Jan 19, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Therapeutic management of hyperlipoproteinemia (a)
Constantine E Kosmas1, Andreas Sourlas2, Gordon Mallarkey3
1Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA.
Insights
Elevated lipoprotein (a) [Lp(a)] is a major cardiovascular disease risk. This review discusses current and emerging therapies, including statins and novel treatments like PCSK9 inhibitors, to manage hyperlipoproteinemia (a).
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Cardiovascular disease (CVD) remains the leading global cause of mortality.
- Elevated plasma lipoprotein (a) [Lp(a)] is a significant, independent risk factor for CVD and calcific aortic valve stenosis.
Purpose of the Study:
- To review and discuss current and emerging therapeutic strategies for managing hyperlipoproteinemia (a).
- To assess the potential impact of reducing Lp(a) levels on cardiovascular risk.
Main Methods:
- Review of current clinical and epidemiological data.
- Analysis of existing and investigational therapeutic interventions for hyperlipoproteinemia (a).
Main Results:
- Established therapies like aspirin, niacin, estrogens, and statins may help mild to moderate Lp(a) elevations.
- Emerging treatments including PCSK9 inhibitors, Lp(a) apheresis, and novel antisense oligonucleotides show promise for severe cases.
Conclusions:
- Effective management of hyperlipoproteinemia (a) is crucial for reducing cardiovascular risk.
- A range of therapeutic options exist, from traditional medications to novel agents, offering potential benefits for patients with elevated Lp(a).
Abstract:
Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide. Several clinical and epidemiological studies have demonstrated that an elevated plasma concentration of lipoprotein (a) [Lp(a)] is a causative and independent major risk factor for the development of CVD, as well as calcific aortic valve stenosis. Thus, the therapeutic management of hyperlipoproteinemia (a) has received much attention, as significant reductions in Lp(a) levels may, potentially, favorably affect cardiovascular risk. Aspirin, niacin, estrogens, and statins, which act on different molecular pathways, may be prescribed to patients with mild or modest elevations of Lp(a) levels. Other therapeutic interventions, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Lp(a) apheresis, and the novel antisense oligonucleotides APO(a)-Rx and APO(a)-LRx, which are being evaluated in ongoing clinical trials, have provided some promising results and can potentially be used in severe cases of hyperlipoproteinemia (a). This review aims to present and discuss the current clinical and scientific data pertaining to the therapeutic options for the management of hyperlipoproteinemia (a).
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Nephrotic Syndrome II : Assessment and Medical Management
Cholesterol: Significance and Regulation
Considering cholesterol and...

